China's Sinovac Draws Criticism For Reporting H1N1 Vaccine Success
This article was originally published in PharmAsia News
The claim of China's Sinovac Biotech that initial trials of its H1N1 flu vaccine were successful has drawn criticism of some foreign health officials as being precipitous. The head of the U.S. National Institute for Allergy and Infectious Diseases was among the officials who said it was impossible to evaluate Sinovac's claim of safety based on testing of only a single dose of the vaccine. He and others noted the company did not reveal the size of the dose, the amount of the virus used or if the dose was administered as a booster to the immune system. Sinovac said the single shot produced flu antibodies and side effects were similar to those resulting from a typical flu shot. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.